Logo

Alnylam Pharmaceuticals, Inc.

ALNY

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include… read more

Healthcare

Biotechnology

22 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$205.52

Price

+0.02%

$0.04

Market Cap

$27.440b

Large

Price/Earnings

37x

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

+26.1%

EBITDA Margin

+17.7%

Net Profit Margin

+4.2%

Free Cash Flow Margin

+26.1%

EBITDA Margin

+17.7%

Net Profit Margin

+4.2%

Free Cash Flow Margin
Revenue

$4.804b

+15.4%

1y CAGR

+34.5%

3y CAGR

+45.0%

5y CAGR
Earnings

$807.988m

+84.0%

1y CAGR

+111.2%

3y CAGR

+98.7%

5y CAGR
EPS

$5.92

+80.7%

1y CAGR

+108.6%

3y CAGR

+97.0%

5y CAGR
Book Value

$1.354b

$5.559b

Assets

$4.205b

Liabilities

$1.267b

Debt
Debt to Assets

22.8%

1.4x

Debt to EBITDA
Free Cash Flow

$542.543m

+37.8%

1y CAGR

+343.0%

3y CAGR

+284.0%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases